Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (such as clopidogrel) is recommended for 1 year after myocardial infarction (MI) to reduce the risk of major adverse cardiovascular events (MACE), with practice guidelines supporting ticagrelor or prasugrel over clopidogrel because of improved clinical outcomes.1 However, the benefit of dual antiplatelet therapy in improving clinical outcomes can only occur if patients take their medications. Yet medication adherence is suboptimal after MI, with a report from 2008 indicating that 1 in 4 patients did not fill their initial cardiac medication prescriptions in the first month after MI, which is associated with higher mortality and cardiovascular events.2 Recent studies estimate that the average proportion of time a patient takes a prescribed P2Y12 inhibitor over 1 year ranges from a high of 76% for clopidogrel to a low of 68% for ticagrelor after stent implantation.3
Jackevicius CA, Ko DT. Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction. JAMA. 2019;321(1):37–39. doi:10.1001/jama.2018.20396
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: